Congress wants Vytorin ad info

Share this article:

Reps. John Dingell and Bart Stupak aren't only interested in Lipitor advertising. In the wake of the release of Enhance trial data, the duo sent letters to Merck and Schering-Plough vowing an investigation and making clear that DTC ads for the drug would be a major focus.

“Given the frequency of Vytorin advertisements, it concerns us that a study showing that Vytorin provides no increased benefit was not issued for nearly two years while (DTC ads) were carried on the airwaves,” they wrote. “This situation raises concerns that the drug companies and their advertisement agencies profited at the significant expense of patients' health.” 
Share this article:
close

Next Article in Features

Email Newsletters

More in Features

Antidote: On Cystic Fibrosis treatments

Antidote: On Cystic Fibrosis treatments

Recent treatments in CF, including the inhaled antibiotic Tobramycin, have increased lifespan well into adulthood.

The $3 generic and the $1,000 pill: pharma outsiders just don't get it

The $3 generic and the $1,000 pill: pharma ...

What do you call the people who treat medical breakthroughs as if they were bank heists? Malicious? Uninformed? Not with it?

Leadership Exchange Uncut : The Agency-Client Relationship

Leadership Exchange Uncut : The Agency-Client Relationship

Click the above link to access MM&M's first Leadership Exchange Uncut e-book, "The Agency-Client Relationship"